Related Experiment Video
Updated: Apr 16, 2026
Osteoclast Derivation from Mouse Bone Marrow
Published on: November 6, 2014
Regulatory Tweak/Fn14 signaling pathway as a potent target for controlling bone loss
Yan-Ying Du1, Yan-Xia Zhao1, Yu-Ping Liu1
1Department of Trauma Orthopedics, Tengzhou Central People's Hospital, Shandong, PR China.
Abstract:
Metabolic bone diseases, such as rheumatoid arthritis (RA) and osteoporosis, are characterized as imbalance between bone formation and bone resorption, leading to bone microarchitecture damage and bone mineral density loss. Bone loss is huge threat for older people's health, which imposes a heavy financial burden on patients and their families. However, the effectiveness of bone loss treatment in clinical practice is limited. With the understanding of the molecular and cellular regulators and mediators of bone remodelling, we know that some signaling pathways and inflammatory cytokines play important roles in the development of RA and osteoporosis. The increasing evidence showed that tumor necrosis factor (TNF)-like weak inducer of apoptosis (Tweak)/fibroblast growth factor-inducible 14 (Fn14) signalling controls a variety of cellular activities in biological processes, such as proliferation, differentiation, and apoptosis and has diverse biological functions in pathological mechanisms like inflammation that are associated with the process of bone metabolism. Recent studies suggest that the interactions between Tweak/Fn14 play critical roles in osteoblast and osteoclast differentiation and apoptosis, especially in those rheumatoid arthritis patients. These findings suggest that interventions targeting Tweak/Fn14 signaling pathway to regulate osteoblast-osteoclast coupling according to its biological effects, which results in promoting osteoblast formation and inhibiting osteoclast resorption, may be a promising approach for bone loss prevention and treatment in the near future.
Insights
Targeting the Tweak/Fn14 pathway shows promise for treating metabolic bone diseases like rheumatoid arthritis and osteoporosis. This approach aims to balance bone formation and resorption, potentially preventing bone loss in older adults.
Area of Science:
- Biochemistry and Molecular Biology
- Immunology
- Orthopedics
Background:
- Metabolic bone diseases, including rheumatoid arthritis (RA) and osteoporosis, involve an imbalance in bone remodeling, leading to microarchitecture damage and reduced bone mineral density.
- Bone loss poses a significant health threat to the elderly, causing substantial financial and personal burdens, with current treatments having limited effectiveness.
- Understanding the molecular regulators of bone remodeling reveals the critical roles of specific signaling pathways and inflammatory cytokines in RA and osteoporosis pathogenesis.
Purpose of the Study:
- To investigate the role of the tumor necrosis factor (TNF)-like weak inducer of apoptosis (Tweak)/fibroblast growth factor-inducible 14 (Fn14) signaling pathway in bone metabolism.
- To explore the potential of targeting the Tweak/Fn14 pathway for therapeutic interventions in metabolic bone diseases.
Main Methods:
- Review of current scientific literature on Tweak/Fn14 signaling and its involvement in bone remodeling.
- Analysis of the impact of Tweak/Fn14 on osteoblast and osteoclast differentiation, proliferation, and apoptosis.
Main Results:
- The Tweak/Fn14 signaling pathway is implicated in regulating cellular activities crucial for bone metabolism, including proliferation, differentiation, and apoptosis.
- Evidence suggests Tweak/Fn14 interactions critically influence osteoblast and osteoclast differentiation and apoptosis, particularly in rheumatoid arthritis patients.
- This pathway modulates inflammation, a key factor in the development of metabolic bone diseases.
Conclusions:
- Targeting the Tweak/Fn14 signaling pathway offers a promising therapeutic strategy for metabolic bone diseases.
- Interventions aimed at modulating Tweak/Fn14 can potentially restore the balance of osteoblast-osteoclast coupling, promoting bone formation and inhibiting resorption.
- This approach may lead to effective future treatments for bone loss prevention and management, especially in conditions like RA and osteoporosis.
More Related Videos
Related Concept Videos
01:40Bone Remodeling
01:31Osteoclasts in Bone Remodeling
01:17Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
01:29Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
01:31Bone Remodeling and Repair
01:25Role of Vitamins in Maintaining Bone Health
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...